{"result": "(\"entity\"<|>METOTREXATO<|>EVENT<|>Metotrexato is a medication that affects folic acid levels and is associated with various side effects including dizziness and hair loss.)\n##\n(\"entity\"<|>ISONIACIDA<|>EVENT<|>Isoniazid is a medication that can lead to vitamin B6 deficiency due to malabsorption.)\n##\n(\"entity\"<|>COLISTIRAMINA<|>EVENT<|>Colestyramine is a medication that can cause malabsorption of fat-soluble vitamins and other nutrients.)\n##\n(\"entity\"<|>DIURÉTICOS<|>EVENT<|>Diuretics are medications that can lead to nutrient deficiencies in patients with chronic liver disease.)\n##\n(\"entity\"<|>HIPERTENSIÓN PORTAL<|>EVENT<|>Portal hypertension is a condition that can lead to nutrient deficiencies due to various factors.)\n##\n(\"entity\"<|>CIRROSIS<|>EVENT<|>Cirrhosis is a chronic liver disease that can result in low levels of certain vitamins and minerals.)\n##\n(\"entity\"<|>DIETA DE MUY BAJO CONTENIDO CALÓRICO<|>EVENT<|>Very low-calorie diets are associated with significant weight loss and various health claims.)\n##\n(\"entity\"<|>HIPOALBUMINEMIA<|>EVENT<|>Hypoalbuminemia is a condition that can contribute to nutrient deficiencies in patients with liver disease.)\n##\n(\"entity\"<|>OBESIDAD<|>EVENT<|>Obesity is a condition that can be treated through dietary interventions and is discussed in the context of diet therapy.)\n##\n(\"relationship\"<|>METOTREXATO<|>DIETA DE MUY BAJO CONTENIDO CALÓRICO<|>Metotrexato can lead to nutrient deficiencies that may be relevant in the context of very low-calorie diets<|>5)\n##\n(\"relationship\"<|>ISONIACIDA<|>DIETA DE MUY BAJO CONTENIDO CALÓRICO<|>Isoniazid can cause deficiencies that may affect dietary management in very low-calorie diets<|>5)\n##\n(\"relationship\"<|>COLISTIRAMINA<|>DIETA DE MUY BAJO CONTENIDO CALÓRICO<|>Colestyramine can lead to malabsorption issues that are important in the context of very low-calorie diets<|>5)\n##\n(\"relationship\"<|>DIURÉTICOS<|>CIRROSIS<|>Diuretics can exacerbate nutrient deficiencies in patients with cirrhosis<|>6)\n##\n(\"relationship\"<|>HIPERTENSIÓN PORTAL<|>CIRROSIS<|>Portal hypertension is a common complication of cirrhosis that can lead to nutrient deficiencies<|>6)\n##\n(\"relationship\"<|>OBESIDAD<|>DIETA DE MUY BAJO CONTENIDO CALÓRICO<|>Very low-calorie diets are often used as a treatment for obesity<|>7)\n<|COMPLETE|>", "input": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": [{"role": "user", "content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: del HDL colesterol.\n         •  El metotrexato favorece el déficit de ácido fólico por su unión a la dihidrofolato-reductasa.                                                 Como efectos secundarios destacan: mareos, fatiga, caída de cabello y uñas frágiles, es-\n         •  La isoniacida favorece el déficit de vitamina B6, por malabsorción.                                                                           treñimiento, etc. Además de ello pueden observarse también casos de hiperuricemia, gota\n         •  La colestiramina favorece la malabsorción de vitaminas liposolubles (A, D y K), vitamina                                                      o colelitiasis.\n            B12, ácido fólico y hierro.                                                                                                                   Referencias:\n         Por otro lado, en pacientes con enfermedades hepáticas son frecuentes los déficits de mi-                                                        • Agostoni C, Bresson J-L, Fairweather-Tait S, Flynn A, Golly I, Korhonen H, et al; EFSA Panel on Dietetic Products, Nutrition and\n                                                                                                                                                            Allergies (NDA). Very low calorie diet (VLCD) related health claims. EFSA Journal. 2011;9(6):2271.\n         cronutrientes por factores como baja ingesta, restricciones dietéticas, alteraciones de la                                                       • Vidal Casariego A, Calleja Fernández A, Kyriakos G, Villar Taibo R. Tratamiento dietético de la obesidad. En: de Luis DA, Bellido Guerrero D,\n         absorción intestinal, la presencia de hipertensión portal o hipoalbuminemia, pérdidas por                                                          García Luna PP, Olveira Fuster G, eds. Dietoterapia, nutrición clínica y metabolismo. 3.ªed. Toledo: Aula Médica; 2017. p. 22-123..\n         diarrea y tratamientos (p. ej., diuréticos). En pacientes                    con enfermedad         hepática     crónica\n         pueden tener niveles bajos de zinc, selenio y magnesio. Los déficits de vitaminas hidrosolu-                                                     El MET o equivalente metabólico es:\n         bles son frecuentes en cirróticos con alcoholismo activo. Las concentraciones plasmáticas                                                    46\n         bajas de vitaminas liposolubles pueden ser más prevalentes en pacientes con colestasis                                                           A. La cantidad de oxígeno necesaria para alcanzar la frecuencia máxima.\n         que en la cirrosis.                                                                                                                              B. La energía consumida durante un minuto de ejercicio realizado a frecuencia máxima.\n         Referencias:                                                                                                                                     C. La energía consumida en reposo durante un minuto.\n         • San Miguel Samano MT, Sánchez Méndez JL. Interacciones alimento/medicamento. Inf Ter Sist Nac Salud. 2011;35:3-12.\n         • Serrano Aguayo MP, Sousa Martín JM, Sendra Fernández C. Soporte nutricional en la hepatopatía crónica y trasplante hepático.                   D.  Ninguna de las anteriores.\n           En: de Luis DA, Bellido Guerrero D, García Luna PP, Olveira Fuster G, eds. Dietoterapia, nutrición clínica y metabolismo. 3.ª ed. Toledo:\n           Aula Médica; 2017. p. 269-88.\n         • Ramos Martínez T, Guindel Jiménez C, Ballesteros Pomar MD. Interacción entre dieta y fármacos. En: de Luis DA, Bellido Guerrero D,\n           García Luna PP, Olveira Fuster G, eds. Dietoterapia, nutrición clínica y metabolismo. 3.ª ed. Toledo: Aula Médica; 2017. p. 705-16.            COMENTARIO\n                                                                                                                                                          EL MET es la cantidad de oxígeno necesaria para el mantenimiento durante 1 minuto de las\n         ¿Cuál de las siguientes afirmaciones es falsa en relación con las dietas de muy                                                                  funciones metabólicas del organismo con el individuo en reposo y sentado. 1 MET equivale\n     45                                                                                                                                                   a 3,5 ml*kg*min.         Como la cantidad de oxígeno consumida es directamente proporcional\n         bajo contenido calórico?                                                                                                                         al consumo energético, este dato podría equivaler a la energía consumida en estado de\n         A. Suelen producir pérdidas de 1,5-2,5 kg por semana.                                                                                            reposo en un minuto.\n         B. No deben mantenerse por un tiempo superior a las 16 semanas.                                                                                  La prescripción mediante MET es una aplicación adecuada en sujetos aparentemente sa-\n         C. Pueden producir hiperuricemia.                                                                                                                nos y en aquellos con valores altos de consumo máximo de oxígeno (VO2 máx), pero resulta\n         D.  El contenido calórico diario no superará las 600 kcal.                                                                                       menos aplicable en personas con enfermedad cardiorrespiratoria o en individuos con baja\n                                                                                                                                                          capacidad funcional. Mediante las tablas apropiadas se pueden obtener los MET de cada\n                                                                                                                                                          tipo de ejercicio físico\n######################\nOutput:"}, {"role": "assistant", "content": "(\"entity\"<|>AGOSTONI C<|>PERSON<|>Agostoni C is a researcher mentioned in the context of dietary products and nutrition.)\n##\n(\"entity\"<|>BRESSON J-L<|>PERSON<|>Bresson J-L is a researcher involved in the EFSA Panel on Dietetic Products, Nutrition and Allergies.)\n##\n(\"entity\"<|>FAIRWEATHER-TAIT S<|>PERSON<|>Fairweather-Tait S is a researcher associated with dietary products and nutrition studies.)\n##\n(\"entity\"<|>FLYNN A<|>PERSON<|>Flynn A is a researcher mentioned in the context of dietary products and nutrition.)\n##\n(\"entity\"<|>GOLLY I<|>PERSON<|>Golly I is a researcher involved in the EFSA Panel on Dietetic Products, Nutrition and Allergies.)\n##\n(\"entity\"<|>KORHONEN H<|>PERSON<|>Korhonen H is a researcher associated with dietary products and nutrition studies.)\n##\n(\"entity\"<|>VIDAL CASARIEGO A<|>PERSON<|>Vidal Casariego A is a researcher involved in dietary treatment of obesity.)\n##\n(\"entity\"<|>CALLEJA FERNÁNDEZ A<|>PERSON<|>Calleja Fernández A is a researcher mentioned in the context of dietary treatment.)\n##\n(\"entity\"<|>KYRIAKOS G<|>PERSON<|>Kyriakos G is a researcher involved in dietary treatment of obesity.)\n##\n(\"entity\"<|>VILLAR TAIBO R<|>PERSON<|>Villar Taibo R is a researcher mentioned in the context of dietary treatment.)\n##\n(\"entity\"<|>DE LUIS DA<|>PERSON<|>De Luis DA is an editor involved in the publication of clinical nutrition and metabolism.)\n##\n(\"entity\"<|>AULA MÉDICA<|>ORGANIZATION<|>Aula Médica is a publishing house that published works on diet therapy and clinical nutrition.)\n##\n(\"entity\"<|>EFSA<|>ORGANIZATION<|>The European Food Safety Authority (EFSA) is an agency that provides scientific advice on food safety and nutrition.)\n##\n(\"entity\"<|>NDA<|>ORGANIZATION<|>The NDA Panel is part of the EFSA that focuses on dietetic products, nutrition, and allergies.)\n##\n(\"entity\"<|>DIETOTERAPIA<|>EVENT<|>Dietotherapy is a clinical practice discussed in the context of nutrition and metabolism.)\n##\n(\"relationship\"<|>AGOSTONI C<|>EFSA<|>Agostoni C is a researcher contributing to studies under the EFSA's guidance on dietetic products and nutrition<|>7)\n##\n(\"relationship\"<|>BRESSON J-L<|>EFSA<|>Bresson J-L is a researcher contributing to studies under the EFSA's guidance on dietetic products and nutrition<|>7)\n##\n(\"relationship\"<|>FAIRWEATHER-TAIT S<|>EFSA<|>Fairweather-Tait S is a researcher contributing to studies under the EFSA's guidance on dietetic products and nutrition<|>7)\n##\n(\"relationship\"<|>FLYNN A<|>EFSA<|>Flynn A is a researcher contributing to studies under the EFSA's guidance on dietetic products and nutrition<|>7)\n##\n(\"relationship\"<|>GOLLY I<|>EFSA<|>Golly I is a researcher contributing to studies under the EFSA's guidance on dietetic products and nutrition<|>7)\n##\n(\"relationship\"<|>KORHONEN H<|>EFSA<|>Korhonen H is a researcher contributing to studies under the EFSA's guidance on dietetic products and nutrition<|>7)\n##\n(\"relationship\"<|>VIDAL CASARIEGO A<|>DIETOTERAPIA<|>Vidal Casariego A is involved in dietary treatment practices discussed in dietotherapy<|>6)\n##\n(\"relationship\"<|>CALLEJA FERNÁNDEZ A<|>DIETOTERAPIA<|>Calleja Fernández A is involved in dietary treatment practices discussed in dietotherapy<|>6)\n##\n(\"relationship\"<|>KYRIAKOS G<|>DIETOTERAPIA<|>Kyriakos G is involved in dietary treatment practices discussed in dietotherapy<|>6)\n##\n(\"relationship\"<|>VILLAR TAIBO R<|>DIETOTERAPIA<|>Villar Taibo R is involved in dietary treatment practices discussed in dietotherapy<|>6)\n##\n(\"relationship\"<|>DE LUIS DA<|>AULA MÉDICA<|>De Luis DA is an editor for works published by Aula Médica on diet therapy and clinical nutrition<|>8)\n<|COMPLETE|>"}]}